Encompass Health (EHC) is a Healthcare company in the Medical Care Facilities industry. It has a market capitalization of $13.50B, a trailing price-to-earnings ratio of 22.4 and a free-cash-flow yield of 3.1%. Over the most recent reported fiscal year, revenue grew 10.5% and free cash flow per share grew 21.9%. Nama's AI scorecard rates it Buy, 6.5 out of 10. On 12-month momentum it ranks in the middle band of its market.
AI scorecard
Buy · 6.5/10
Positive, at the low end of Buy. As of Nov 7, 2026.
Momentum
Middle · +6.4% over 12 months ex. last
Middle fifth of its market on the past year's move.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-4.1%
How far the last close sits under the highest price of the past five years.
Market cap
$13.50B
Trailing P/E
22.4
Price / book
5.2
Price / sales
2.1
FCF yield
3.1%
Dividend yield
0.6%
Gross margin
95.8%
Operating margin
18.0%
Net margin
10.0%
Revenue growth (YoY)
+10.5%
Revenue growth (3-yr annual)
+10.9%
EPS growth (YoY)
+23.2%
FCF/share growth (YoY)
+21.9%
Beta
0.6
Exchange
NYSE
Sector
Healthcare
Industry
Medical Care Facilities
EHC earnings
Next report: Feb 4, 2027 (Q4 2026, EPS estimate $1.61).
Beat the EPS estimate in 4 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Oct 28, 2026
$1.52
$1.36
+11.8%
$1.61B
Q2 2026
Aug 5, 2026
$1.55
$1.48
+4.7%
$1.60B
Q1 2026
Apr 30, 2026
$1.60
$1.49
+7.4%
$1.59B
Q4 2025
Feb 5, 2026
$1.46
$1.30
+12.3%
$1.54B
EHC analyst price target
Median target $155.00 from 12 analysts, ranging $142.00 – $177.00.
Nama's AI scorecard currently rates Encompass Health Buy (6.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is EHC's P/E ratio?
Encompass Health trades at a trailing price-to-earnings ratio of 22.4.
When does EHC report earnings?
Encompass Health's next scheduled report is on Feb 4, 2027. Analysts expect EPS of $1.61.
What is the EHC price target?
The median analyst price target from 12 analysts is $155.00, with a range of $142.00 – $177.00.
Is EHC Shariah compliant?
Nama's AAOIFI-style screen reads Encompass Health as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.